Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH) (STRONG)
A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is at least 50 years old
- Has a urinary disturbance associated with severe BPH and has a total IPSS score 20 or higher
- Has a QoL score of 3 or higher
- Has a urine volume of 120mL or greater and a Qmax of below 15mL/sec
- Has a PRV of below 100mL
- Voluntarily decides to participate in this trial and sign with informed consent form
Exclusion Criteria:
- Has been administered silodosin
- Has been administered an α1A-adrenoceptor blocker within one month
- Has been prescribed antiandrogens except 5α-reductase inhibitors within a year
- Has had phytotherapy within 3 months
- Has had prostatectomy
- Has had intrapelvic radiation therapy
- Has had transurethral microwave hyperthermia of transurethral needle ablation
- Is suspected to have implications that are likely to affect urine passing such as neurogenic bladder, bladder calculus or active urinary tract infection (UTI).
- Is conducting self-catherterization
- Has a renal impairment with a serum creatinine of 2.0mg/dL or greater
- Has severe hepatic disorders (hepatic insufficiency, cirrhosis, jaundice, hepatoma) or has a total bilirubin of 2.5mg/dl or higher or has AST/ALT 2.5 times higher than the normal (upper) level
- Has suffered from a severe arrhythmia, cardiac failure, cardiac infarction, unstable angina, cerebral infarction within 6 months
- Has experienced allergy to α1 receptor blockers
- Has orthostatic hypotension around the time of Screening Visit
- Has participated in other clinical trials within 8 weeks prior to Screening Visit
- Has a Prostate specific antigen(PSA) of higher 10ng/mL or has been diagnosed with tumor identified by a biopsy even though he has a PSA of lower 10ng/mL (Patient who has been administered 5α-reductase inhibitors for more than 3 months are presumed to have 2 times higher than their actual PSA levels)
- Has been taking unstable dosing of 5α-reductase inhibitors like finasteride or dutasteride for the past 3 months or is expected to change the dosage during the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Silodosin
Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
|
Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total International prostate symptom score(IPSS) score before and after treatment
Time Frame: For 12 weeks
|
Assess the improvement of lower urinary tract symptoms with change in total IPSS score before and after treatment.
|
For 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life(QoL) score before and after treatment
Time Frame: For 12 weeks
|
Assess the improvement of lower urinary tract symptoms with change in QoL score before and after treatment.
|
For 12 weeks
|
|
Maximal urinary flow rate(Qmax) before and after treatment
Time Frame: For 12 weeks
|
Assess the improvement of lower urinary tract symptoms with change in Qmax before and after treatment.
|
For 12 weeks
|
|
Voiding score of IPSS before and after treatment
Time Frame: For 12 weeks
|
Assess the improvement of lower urinary tract symptoms with change in voiding scores before and after treatment.
|
For 12 weeks
|
|
Storage scores of IPSS before and after treatment
Time Frame: For 12 weeks
|
Assess the improvement of lower urinary tract symptoms with change in storage scores before and after treatment.
|
For 12 weeks
|
|
Post void residual urine volume(PVR) before and after treatment
Time Frame: For 12 weeks
|
Assess the improvement of lower urinary tract symptoms with change in post void residual urine volume(PRV) before and after treatment.
|
For 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: G.S. Park, Prof, Chonnam National Univ.
- Principal Investigator: D.Y. Yang, Prof, Kangdong Sacred Heart
- Principal Investigator: K.H. Moon, Prof, Yeongnam Univ. Medical
- Principal Investigator: N.C. Park, Pusan National Univ. Hospital
- Principal Investigator: S.W. Kim, Prof, Seoul National Univ. Hospital
- Principal Investigator: S.W. Lee, Prof, Samsung Medical Center
- Principal Investigator: S.W. Kim, Prof, Seoul St. Mary'S Hospital
- Principal Investigator: D.G. Moon, Prof, Korea Univ. Guro hospital
- Principal Investigator: J.K. Park, Prof, Chunbuk National Univ. Hospital
- Principal Investigator: T.Y. Ahn, Prof, Asan Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Prostatic Diseases
- Prostatic Hyperplasia
- Hyperplasia
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Silodosin
Other Study ID Numbers
Other Study ID Numbers
- CWP-SDS-403
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.